/

IRON

Disc Medicine, Inc.Open

57.64−2.84 −4.71%USD

NasdaqGM · as of Oct 13, 12:41 ET · 15m delay

Open

60.16

Prev close

60.48

Day range

56.4760.48

52-week range

40.0099.50

Volume

237.98K0.50×

Mkt cap

2.21B

P/E ttm

—

Fwd P/E

-8.14

EPS ttm

-6.58

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−42.07%

Price Chart

Yahoo Finance · delayed

IRONOct 13, 2026O 60.16H 60.48L 56.47C 57.64−2.84 (−4.70%)Vol 237.98K

SMA 5072.83
SMA 20071.00

1Y change −17.54% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IRON Disc Medicine, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.50%
1 month: −17.73%
3 months: −23.16%
6 months: −18.22%
Year to date: −27.41%
1 year: −19.90%

Valuation & ownership

Market cap: 2.21B
Enterprise value: 1.67B
P/E (ttm): —
Forward P/E: -8.14
PEG ratio: —
Price / book: 3.43
Price / sales (ttm): —
EV / EBITDA: -6.21
EPS (ttm): -6.58
EPS (forward): -7.08
Beta (5y monthly): 2.11
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 38.39M
Float: 32.91M
Short % of float: 22.08%
Short ratio (days): 12.69
Held by insiders: 7.84%
Held by institutions: 114.11%
Avg volume (3m): 479.43K
50-day average: 73.21
200-day average: 71.11
52-week change: −19.90%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 22.5
vs 50-day SMA: −20.86%
vs 200-day SMA: −18.82%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.08%
Realised vol (20d, ann.): 30.4%
From 52-week high: −42.07%
From 52-week low: +44.10%

ANR

Analyst Consensus

12 analysts

Consensus

Strong buy

1.08 on a 1 (strong buy) – 5 (sell) scale

Mean target

103.17

+78.98% implied

Low 83.00Median 100.00High 128.00

Recommendation trend

Now13 / 0 / 0
1m ago13 / 0 / 0

DES

About Disc Medicine, Inc.

Yahoo Finance profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 165
Headquarters: Watertown, MA, United States
Website: discmedicine.com
Officers: Dr. Donald William Nicholson Ph.D. Executive Chairman
Dr. John D. Quisel Esq., J.D., Ph.D. CEO, President & Director
Ms. Jean M. Franchi CPA

SEAS

Seasonality · IRON

2020–2026 · monthly returns

Strongest month Jun +10.08%Weakest month Dec −9.45%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.6	-13.8	-4.0	3.1	5.5	5.1	5.3	2.1	-16.8	-11.9			−27.4%
2025	-12.0	0.7	-11.6	-0.4	-5.5	13.5	12.8	-0.2	10.8	30.5	8.3	-14.9	+25.3%
2024	13.8	4.4	-9.3	-55.3	21.9	32.8	-4.2	17.7	-3.3	-8.8	41.6	-0.1	+9.8%
2023	10.6	13.6	-15.2	54.5	13.4	19.6	11.7	6.8	-11.3	-2.5	20.5	4.7	+190.4%
2022	-32.6	-30.6	2.2	8.6	-15.2	32.0	-9.5	1.3	5.8	9.8	-4.4	-61.5	−77.2%
2021	7.3	28.8	-10.9	-13.7	5.2	-47.4	-37.1	20.9	-17.9	-5.9	-27.4	5.4	−73.5%
2020									1.8	-10.7	0.3	9.7	−0.0%

INSD

Insider Activity · IRON

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

216.7K shares

Sells, 6 months

249.3K shares

Net shares

−32.6K

Net change in insider shares

−1.10%

Date	Insider	Transaction	Shares	Value
Sep 14, 2026	Quisel John DChief Executive Officer	Conversion of Exercise of derivative security at price 1.01 per share.	36K	$36.36K
Sep 10, 2026	Bitterman Kevin JDirector	Conversion of Exercise of derivative security at price 38.85 - 50.86 per share.	27.1K	$1.22M
Sep 10, 2026	Bitterman Kevin JDirector	Sale at price 70.11 per share.	27.1K	$1.90M
Sep 3, 2026	Bitterman Kevin JDirector	Sale at price 79.96 per share.	1.7K	$135.05K
Sep 2, 2026	Bitterman Kevin JDirector	Sale at price 79.95 - 80.98 per share.	54.5K	$4.37M
Aug 24, 2026	Yu Jonathan Yen-WenChief Operating Officer	Conversion of Exercise of derivative security at price 13.50 per share.	9.1K	$122.80K
Aug 24, 2026	Yu Jonathan Yen-WenChief Operating Officer	Sale at price 82.53 - 83.12 per share.	9.1K	$755.85K
Aug 16, 2026	Quisel John DChief Executive Officer	Conversion of Exercise of derivative security at price 13.50 per share.	33K	$445.50K
Aug 16, 2026	Quisel John DChief Executive Officer	Sale at price 78.11 - 79.84 per share.	33K	$2.61M
Aug 11, 2026	Yu Jonathan Yen-WenChief Operating Officer	Conversion of Exercise of derivative security at price 13.50 per share.	804	$10.85K
Aug 11, 2026	Yu Jonathan Yen-WenChief Operating Officer	Sale at price 82.64 per share.	804	$66.44K
Aug 5, 2026	Khara RahulOfficer	Conversion of Exercise of derivative security at price 14.69 per share.	5K	$73.45K
Aug 5, 2026	Khara RahulOfficer	Sale at price 80.00 per share.	5K	$400.00K
Jul 12, 2026	Quisel John DChief Executive Officer	Conversion of Exercise of derivative security at price 9.86 - 13.50 per share.	33K	$352.37K
Jul 12, 2026	Quisel John DChief Executive Officer	Sale at price 74.27 - 76.05 per share.	33K	$2.47M
Jul 6, 2026	Yu Jonathan Yen-WenChief Operating Officer	Conversion of Exercise of derivative security at price 13.50 per share.	100	$1.35K
Jul 6, 2026	Yu Jonathan Yen-WenChief Operating Officer	Sale at price 82.50 per share.	100	$8.25K
Jun 28, 2026	Khara RahulOfficer	Conversion of Exercise of derivative security at price 14.69 per share.	2.5K	$36.73K
Jun 28, 2026	Khara RahulOfficer	Sale at price 75.00 per share.	2.5K	$187.50K
Jun 25, 2026	Yu Jonathan Yen-WenChief Operating Officer	Conversion of Exercise of derivative security at price 13.50 per share.	300	$4.05K

IRON

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IRON

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Disc Medicine, Inc.

Seasonality · IRON

Insider Activity · IRON

Congress Trades · IRON

Investors Holding IRON

Investors Holding IRON

Congress Trades · IRON

Insider Activity · IRON

Seasonality · IRON

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Disc Medicine, Inc.

Financial Snapshot

Earnings & Dividends

News